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 Diverting Glycolysis to Combat Oxidative 
Stress 
 Edouard  Mullarky and  Lewis  C.  Cantley 
 Abstract  Reactive oxygen species (ROS) are an intricate part of normal cellular 
physiology. In excess, however, ROS can damage all three major classes of macro-
molecules and compromise cell viability. We brieﬂ y discuss the physiology of ROS 
but focus on the mechanisms cells use to preserve redox homeostasis upon oxidative 
stress, with particular emphasis on glycolysis. ROS inhibits multiple glycolytic 
enzymes, including glyceraldehyde 3-phosphate dehydrogenase, pyruvate kinase 
M2, and phosphofructokinase-1. Consistently, glycolytic inhibition promotes ﬂ ux 
into the oxidative arm of the pentose phosphate pathway to generate NADPH. NADPH 
is critically important, as it provides the reducing power that fuels the protein-based 
antioxidant systems and recycles oxidized glutathione. The unique ability of pyru-
vate kinase M2 inhibition to promote serine synthesis in the context of oxidative 
stress is also discussed. 
 Keywords  Oxidative stress •  Glycolysis •  Pentose phosphate pathway •  PKM2 • 
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 Chemical Defi nition and Sources of ROS 
 Reactive oxygen species (ROS) is a vague moniker used to describe a variety of 
oxygen-containing, chemically reactive small molecules, such as superoxide (•O 2 − ), 
the hydroxyl radical (HO•), and hydrogen peroxide (H 2 O 2 ), that cause oxidative 
stress. ROS can be generated from exogenous sources like ionizing radiation or 
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4redox-cycling xenobiotics [ 1 ,  2 ]. Endogenously, ROS are an obligate by-product 
of aerobic metabolism. Typically, molecular oxygen is reduced by single- or 
two- electron mechanisms, yielding superoxide or hydrogen peroxide, respectively. 
Mitochondria are the predominant source of ROS owing to the electron transport 
chain (ETC), but peroxisomes and the endoplasmic reticulum contribute. During 
normal respiration, 1–2 % of molecular oxygen is converted to superoxide owing 
to electron leak at Complexes I and III [ 1 ,  3 ,  4 ]. Perturbations in mitochondrial 
metabolism such as changes in oxygen tension and the actions of mitochondrial 
uncoupling proteins can modulate superoxide production [ 5 ,  6 ]. In addition, 
enzymes including the NADPH oxidases, which are particularly important in 
phagocytic cells, xanthine oxidases, uncoupled nitric oxide synthases, and cyto-
chrome P-450s actively produce ROS [ 7 ]. Redox-active metal ions, such as iron, 
can generate the highly reactive hydroxyl radical from hydrogen peroxide via the 
Fenton reaction [ 8 ]. While diverse reactive oxygen species are commonly grouped 
together under the term ROS, it is important to remember that their chemistry, and 
hence biology, differ substantially. For instance, hydroxyl radicals react with near 
diffusion-limited rate constants with almost any organic molecule. The more limited 
reactivity of hydrogen peroxide enables it to diffuse across membranes and oxidize 
thiols speciﬁ cally, thus making it a more suitable ROS second messenger [ 9 ,  10 ]. 
In general, reactivity comes at the expense of speciﬁ city. 
 Physiology of ROS 
 In excess, ROS can lead to widespread oxidative damage of all three macromolecu-
lar classes—lipids, protein, nucleic acids—and ultimately to cell death via apoptotic 
or necrotic pathways [ 11 ]. For instance, the hydroxyl radical and a protonated form 
of superoxide can initiate dangerous autocatalytic lipid peroxidation [ 11 – 13 ]. ROS 
are mutagenic and may therefore promote tumorigenesis [ 8 ]. Hydroxyl radical–
induced 8-oxoguanine lesions promote genomic G-to-T and C-to-A substitutions 
due to mismatched base pairing [ 14 ]. The hydroxyl radicals produced via ionizing 
radiation or Fenton reactions are such strong oxidants that they can abstract hydrogen 
atoms from a polypeptide backbone to generate a carbon radical [ 8 ,  15 ]. In addition, 
ROS-mediated proline oxidation can result in the cleavage of a protein peptide 
backbone. Amino acid side chains, such as those of methionine and cysteine and 
the aromatic groups of phenylalanine, tryptophan, tyrosine, and histidine, are also 
vulnerable to attack. Protein carbonylation is commonly used as a marker for oxida-
tive stress. Oxidative protein modiﬁ cation can result in protein–protein cross- links. 
For example, the amino group of a lysine residue can attack a carbonyl of another 
protein. Importantly, some of the protein oxidative modiﬁ cations, particularly protein 
cross-links, are resistant to proteasomal degradation and can inhibit the activity of 
the proteasome towards other proteins [ 16 ]. 
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5 In moderate amounts, however, ROS are intricately linked with “normal” cellular 
physiology. In nonphagocytic cells, stimulating tyrosine kinase receptors via epi-
dermal growth factor (EGF), platelet-derived growth factor (PDGF), and vascular 
endothelial growth factor (VEGF) induces a transient increase in cellular ROS [ 8 , 
 17 – 19 ]. The signaling can be attenuated by antioxidant treatment. Nature has 
exploited the redox sensitivity of cysteine thiol groups to develop biochemical 
switches poised to functionally respond to changes in cellular ROS [ 20 ,  21 ]. 
Several of these thiol switches respond to growth factor stimulation–induced 
ROS. Speciﬁ cally, ROS reversibly inhibits catalytic cysteine residues of the lipid 
phosphatase PTEN (phosphatase and tensin homolog) by disulﬁ de bond formation 
and protein tyrosine phosphatases (PTPs) by cyclic sulfonamide formation. Thus, 
ROS-mediated phosphatase inhibition serves to enhance phosphatidylinositol-3 
kinase (PI3K) and tyrosine kinase proliferative and survival signaling [ 20 ,  22 ,  23 ]. 
Most cytosolic protein thiol groups have a pKa greater than the physiological pH 
and are thus protonated and insensitive to the more mild forms of ROS such as 
hydrogen peroxide. However, the thiol switch local environment signiﬁ cantly 
reduces the cysteine side chain pKa such that the more nucleophilic thiolate anion 
predominates [ 9 ,  20 ]. Thus, the thiolate anion is sensitized to changes in cellular 
ROS and ready to respond. In addition, thiols can react with electrophilic species 
via a Michael addition mechanism to form a covalent adduct potentially triggering 
the thiol switch [ 9 ]. 
 ROS can both activate and repress transcription factors via thiol switch–based 
mechanisms. Rather than inhibiting enzymatic activity, as with the phosphatases 
discussed above, thiol oxidation induces conformational changes to regulate tran-
scription factor subcellular localization. In  Saccharomyces cerevisiae , for example, 
the AP-1-like transcription factor Yap1p responds to oxidative stress via H 2 O 2 - 
induced inter- and intramolecular disulﬁ de exchanges that result in a conforma-
tional change in Yap1p. Conformational remodeling masks the nuclear export signal 
promoting nuclear stabilization and antioxidant gene expression. The Yap1p thiol 
switch thus permits a yeast cell to regulate an antioxidant gene program that 
responds to ROS directly [ 20 ]. Similarly, mammalian cells utilize a thiol redox 
switch to induce an antioxidant gene expression program in response to oxidative 
and xenobiotic stresses. Under “normal” conditions, Keap1 (Kelch-like ECH- 
associated protein 1) negatively regulates NRF2 (nuclear factor erythroid 2-related 
factor 2) by acting as an adapter for a CUL3 E3 ligase that targets NRF2 for ubiqui-
tination and proteasomal degradation [ 24 ]. Keap1 contains multiple cysteine resi-
dues that are targeted by oxidants, including ROS and exogenous or endogenous 
electrophiles, to disrupt NRF2 repression [ 25 – 28 ]. Thus stabilized, NRF2 can 
induce expression of approximately 200 genes to promote both antioxidant and 
xenobiotic responses. Important NRF2 targets include glutathione (GSH) synthesis 
genes, such as the catalytic (GCLC) and modiﬁ er (GCLM) subunits of the rate- 
limiting step in GSH synthesis, and glutathione reductase (GSR). 
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6 Biochemical Mechanisms that Preserve Redox Homeostasis 
 In addition to transcriptional responses like that of NRF2, cells employ a number of 
strategies to maintain redox homeostasis. The cytosol is maintained at a negative 
reducing potential of approximately −250 mV using the abundant (1–10 mM) 
tripeptide glutathione (GSH) and its oxidized form (GSSG) as a redox couple 
buffer [ 20 ]. High-catalytic-activity enzymes rapidly scavenge ROS as they are 
produced. Cytoplasmic and mitochondrial isoforms of superoxide dismutase (SOD) 
enhance 10,000-fold the spontaneous dismutation of superoxide to hydrogen 
peroxide [ 29 ]. Peroxisomal catalase (CAT) and glutathione peroxidases (GPx) can 
further degrade hydrogen peroxide to water and molecular oxygen [ 10 ]. Were ROS 
to evade direct enzymatic scavenging and oxidize protein thiols, the parallel thiore-
doxin (Trx) and glutaredoxin (Grx) systems reduce the damage. Trx and Grx are 
small proteins (9–16 kD), which share a dicysteine active site motif (CxxC) in a Trx 
fold [ 30 ]. The Trx mechanism involves a Trx-to-target protein-mixed disulﬁ de that 
is subsequently nucleophilically attacked, by the remaining active site cysteine, to 
form an intramolecular Trx disulﬁ de fully reducing the target protein. Grx prefers to 
attack S-glutathionylated target proteins forming a mixed Grx–glutathione disulﬁ de 
that is resolved by a second GSH molecule releasing reduced Grx and GSSG. Both 
systems are ultimately dependent on cellular NADPH-reducing equivalents to 
regenerate them: Trx reductase (TrxR) and glutathione reductase (GSR) use NADPH 
to reduce oxidized Trx and GSSG, respectively (Fig.  1 ) [ 30 ]. In addition, glutathione 
peroxidases such GPx4 use GSH to reduce lipid and cholesterol peroxides [ 4 ,  31 ]. 
NRF2 activation induces the expression of multiple metabolic enzymes that 
directly generate NADPH, including glucose-6-phosphate dehydrogenase (G6PD), 
6- phosphogluconate dehydrogenase (PGD), isocitrate dehydrogenase (IDH1), and 
malic enzyme (ME1), while downregulating genes for fatty acid synthesis that con-
sume NADPH [ 32 ,  33 ]. This allows NRF2 to stimulate the production of NADPH, 
the fundamental source of cellular reducing power. While catalase does not require 
NADPH for its enzymatic activity, it has an allosteric site for NADPH that main-
tains catalase in its active conformation [ 34 ]. ROS can activate mitogen-activated 
kinase (MAPK) signaling cascades that respond to cellular stress. Under normal 
conditions, ASK1 (apoptosis signaling-regulated kinase) is bound to Trx and 
inhibited. Trx binding requires the Trx dicysteine motif to be reduced. Following 
oxidation, ASK1 is released and free to oligomerize and autophosphorylate. Thus 
activated, ASK1 induces MAPK cascades that activate the p38 and JNK stress 
kinases to promote apoptosis [ 35 ]. Interestingly, the α-arrestin family member 
Trx- interacting protein (TXNIP) seems to integrate glucose availability and ROS. As 
its name indicates, TXNIP forms intermolecular disulﬁ des with Trx, inhibiting it 
and promoting oxidative stress [ 36 ]. TXNIP furthermore regulates the glucose 
transporter Glut1 by suppressing Glut1 mRNA and promoting its internalization via 
clathrin-coated pits. AMP-activated protein kinase (AMPK)—the cellular energy 
sensor—is activated under low-energy conditions to suppress ATP consumption and 
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7increase ATP production. As such, AMPK phosphorylates TXNIP, thereby promoting 
its degradation via the proteasome to stabilize Glut1 mRNA and maintain Glut1 
transporters at the plasma membrane [ 37 ].
 Metabolic Adaptations to ROS 
 Metabolism is profoundly affected by oxidative stress. In excess, oxidation can 
provoke metabolic failure, compromising cell viability by inactivating enzymes of 
glycolysis, the Krebs cycle, and the ETC [ 11 ,  38 ]. For example, oxygen-labile iron–
sulfur clusters, such as those of aconitase or ETC complexes, are often targeted 
[ 4 ,  39 ]. However, metabolism has also evolved to respond to such stresses in an 
adaptive manner. Frequently, the mechanism revolves around thiol-based switches 
that allow the cell to rewire metabolism in a way that promotes an antioxidant 
response independent of transcriptional or signaling pathways. As such, metabolism 
is one of the faster responders; metabolic rewiring is evident within minutes of 
oxidative stress [ 40 ]. We will explore how cells tune glycolytic metabolism to 
cope with oxidative damage. Much of the antioxidant systems ineluctably rest on 
the NADPH to NADP + ratio. Thus, a recurring theme will be how glycolytic ﬂ ux is 


























 Fig. 1  Antioxidant systems that preserve redox homeostasis. Electron (e − ) leak from the electron 
transport chain (ETC) produces superoxide (•O 2 − ). Superoxide dismutase (SOD) converts superox-
ide to hydrogen peroxide. Glutathione peroxidases (GPx) reduce peroxides, such as hydrogen 
peroxide (H 2 O 2 ), oxidizing glutathione (GSH) to GSSG. Reactive oxygen species (ROS) can oxi-
dize proteins. The parallel thioredoxin (Trx) and glutaredoxin (Grx) systems can reduce proteins 
by oxidizing their dicysteine motif or GSH, respectively. Trx reductase (TrxR) and glutathione 
reductase (GSR) consume NADPH to restore Trx and GSH 
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8 The Pentose Phosphate Pathway and NADPH Production 
 After glucose is imported into the cell via GLUT transporters, it is phosphorylated 
by hexokinase (HK) at the 6 position to generate glucose-6-phosphate (G6P). 
Glucose phosphorylation has the dual beneﬁ ts of trapping glucose within the cell 
and providing a trans-membrane concentration gradient to draw more glucose in. 
G6P lies at the nexus of glycolysis, glycogen synthesis—via conversion to glucose-
1- phosphate—and the oxidative arm of the pentose phosphate pathway (ox-PPP). 
The predominant fate of G6P is a function of cell type and metabolic demand. The 
ox-PPP is traditionally considered the predominant producer of cellular NADPH 
and is thus critical for antioxidant defense [ 41 ]. Conceptually, the ox-PPP is distinct 
from the reversible non-oxidative phase of the PPP, which does not produce NADPH 
(Fig.  2 ) [ 42 ]. G6PD catalyzes the ﬁ rst committed and rate-limiting step of the ox-PPP, 
generating one unit of NADPH and 6-phosphoglucolactone [ 34 ]. The unstable 
lactone ring is opened by phosphogluconolactonase to yield 6- phosphogluconate, 































 Fig. 2  Glycolysis and the pentose phosphate pathway (PPP). The PPP is composed of two distinct 
arms, the oxidative branch ( light blue ) and the non-oxidative branch ( gray ). While both arms 
produce ribose-5-phosphate, a precursor for nucleotide synthesis, only the oxidative branch con-
comitantly produces NADPH. Glycolytic ﬂ ux enters the oxidative branch via glucose-6-phosphate 
dehydrogenase (G6PD). Fructose-2,6-bisphosphate (F-2,6-BP) activates phosphofructokinase-1 
(PFK1) to promote glycolysis ( light green ). In response to reactive oxygen species (ROS) and UV 
stress, p53 activates TIGAR (TP53-induced glycolysis and apoptosis regulator). TIGAR degrades 
F-2,6-BP, thereby inhibiting PFK1. This allows glycolytic ﬂ ux to be diverted into the oxidative arm 
and enhances NADPH production to fuel the cellular antioxidant systems. Metabolic enzymes are 
shown in  dark blue 
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9and ribulose-5-phosphate [ 34 ,  43 ]. The net yield per unit of G6P is therefore two 
NADPH and ribulose-5-phosphate. Ribulose-5-phosphate is an immediate precursor 
for the ribose-5-phosphate used in the synthesis of nucleotide sugar moieties. 
The G6P carbon may be recycled back into glycolysis as the non-oxidative arm PPP 
enzyme transketolase produces the glycolytic intermediates glyceraldehyde-3-phos-
phate (G3P) and fructose-6-phosphate (F6P) (Fig.  2 ) [ 34 ,  43 ]. Post-translationally, 
G6PD is regulated by phosphorylation, protein–protein interaction, and translocation 
to the plasma membrane upon growth factor stimulation [ 34 ,  44 – 47 ]. Importantly, 
G6PD is allosterically activated by the NADP + to NADPH ratio [ 34 ,  48 ,  49 ]. Thus, 
as antioxidant enzymes, including those of the Grx and Trx systems, consume 
NADPH to reduce ROS-induced damage, NADP + levels increase, stimulating the 
activity of the ox-PPP to produce more NADPH and maintain cellular reducing power.
 The importance of ox-PPP in protecting against oxidant stress is clearly evident 
from X-linked G6PD deﬁ ciency, the most common human enzyme defect in the 
world. Erythrocytes are sensitive to oxidative stress and are highly dependent on 
ox-PPP to maintain NADPH and reduced GSH. Thus, one well-documented and 
potentially lethal clinical manifestation of G6PD deﬁ ciency is acute hemolytic 
anemia following ingestion of oxidative stress–inducing agents. Such agents include 
the antimalarial primaquine, sulfonamides, and fava beans. Other patients suffer 
from chronic anemia [ 50 ,  51 ]. In agreement with the human pathology, in vitro 
experiments in a variety of cell types show that G6PD inhibition or genetic knock-
out increases sensitivity to oxidizing agents, including exogenous and endogenous 
H 2 O 2 [ 52 ,  53 ]. G6PD knockout increases the apoptotic response of CHO cells 
exposed to ionizing radiation consistent with the role of ROS in apoptosis [ 54 ]. 
Conversely, G6PD overexpression increases resistance to exogenous H 2 O 2 [ 52 ,  53 ]. 
The combination of human and in vitro data argues that the diversion of glycolytic 
ﬂ ux into the ox-PPP pathway plays a vital role in antioxidant defense at both a 
cellular and organismal level. 
 Different cell types likely rely on different metabolic pathways to generate their 
basal level of NADPH. Mutant KRas-driven pancreatic ductal adenocarcinoma cells 
(PDAC) use glutamine-derived malate to generate basal NADPH, via malic enzyme 
(ME1), and keep ROS in check. In PDAC, G6PD knockdown does not affect 
NADPH levels, suggesting that it is not necessary for redox balance [ 56 ]. PDAC 
rely on the non-oxidative PPP branch to promote ribose biogenesis for nucleic acid 
production, hence decoupling it from NADPH synthesis [ 57 ]. In contrast, HEK293T 
cells are not dependent on ME1 but instead use the ox-PPP and folate cycle to generate 
basal NADPH and maintain reduced GSH pools [ 58 ]. Whether ox-PPP activation 
from a more inhibited state due to high NADPH levels under “normal” cellular 
conditions is the predominant NADPH stress response pathway, as some have 
suggested, needs further investigation [ 52 ,  54 ,  59 ]. For example, HEK293T cells 
derive a majority of their NADPH from the ox-PPP with the folate cycle producing 
a  substantial amount [ 58 ]. Knockdown of the folate cycle enzymes methylenetetra-
hydrofolate dehydrogenase 1 (MTHFD1) and MTHFD2 sensitizes HEK293T cells 
to acute hydrogen peroxide and diamide stress, indicating that the folate cycle also 
plays a role in dealing with oxidative stress presumably through its substantial 
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NADPH contribution. Whether folate cycle NADPH production is directly activated 
by ROS stress, like the ox-PPP, remains to be determined. The fact that NRF2 has 
evolved to regulate the expression of the NADPH-generating enzymes IDH1 and 
ME1, in addition to G6PD and PGD, suggests that it is beneﬁ cial to activate NADPH 
production not only via the induction of the ox-PPP [ 28 ]. In the context of ME1 
knockdown PDAC cells, why the increases in NADP + and ROS do not trigger 
increased ox-PPP pathway ﬂ ux directly through G6PD or indirectly via NRF2 is not 
clear and is surprising given that other cell types are known to do so [ 53 ]. 
 Phosphofructokinase-1 Inhibition 
 Once glucose is trapped within the cell as G6P, it undergoes a reversible isomeriza-
tion reaction to fructose-6-phosphate (F-6-P) catalyzed by phosphoglucose isomer-
ase (PGI). Phosphofructokinase-1 (PFK1) subsequently phosphorylates F-6-P at the 
1 position, yielding fructose-1,6-bisphosphate (F-1,6-BP). Importantly, the PFK1 
step is both rate limiting and the ﬁ rst committed step of glycolysis; above PFK1, 
glycolytic intermediates can enter into glycogen synthesis, the ox-PPP, or the 
hexosamine pathway [ 60 ,  61 ]. PFK1 functions as the gatekeeper of glycolysis and 
is therefore highly regulated. ATP and citrate are allosteric inhibitors, while AMP 
and fructose-2,6-bisphosphate (F-2,6-BP) are activators [ 60 ,  61 ]. The exact PFK1 
kinetic parameters are determined by the speciﬁ c subunit composition [ 62 ]. 
Releasing ATP-based PFK1 inhibition is important to stimulate glucose metabolism 
in proliferating cells [ 63 ]. This is in part achieved by F-2,6-BP-induced PFK1 acti-
vation. F-2,6-BP is produced by phosphofructokinase-2 (PFK2) phosphorylating 
F-6-P at the 2 position (Fig.  2 ). PFK2 is a bifunctional enzyme containing a kinase 
domain and bisphosphatase (BPase) domain at the N and C-termini, respectively 
[ 64 ,  65 ]. Thus, the cellular F-2,6-BP concentration depends on the rates of the two 
opposing activities. The kinase and BPase activities are regulated transcriptionally and 
post-translationally via, for example, hormonal stimulation [ 64 ,  65 ]. Conceptually, 
the F-2,6-BP shunt not only provides a PFK1 feed-forward mechanism to accelerate 
glycolysis when intracellular F-6-P accumulates but also helps decouple glycolytic 
ﬂ ux from the cellular ATP charge. Unsurprisingly, PFK1 and PFK2 are deregulated 
in cancer [ 64 ,  66 ]. 
 TIGAR (TP53-induced glycolysis and apoptosis regulator) was identiﬁ ed as a 
p53 target gene induced by ionizing radiation [ 67 ,  68 ]. TIGAR has a single BPase 
activity that degrades F-2,6-BP to F-6-P [ 64 ,  65 ]. By decreasing F-2,6-BP levels, 
TIGAR inhibits glycolytic ﬂ ux downstream of PFK1. PFK1 inhibition allows the 
G6P and F6P pools to accumulate as their consumption is greatly diminished. The 
increased G6P can ﬂ ow into the ox-PPP to generate NADPH. Consistent with this, 
TIGAR knockdown, or inhibition of upstream positive regulators, leads to increased 
ROS and a decrease in NADPH and reduced GSH [ 68 – 71 ]. The intestinal crypts of 
TIGAR knockout mice subjected to whole body irradiation are acutely more apop-
totic and have a greater difﬁ culty in regenerating themselves compared with those 
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of wild-type animals [ 72 ]. The apoptotic response is suggestive of a failure in 
dealing with ROS; left unchecked, ROS can trigger apoptosis. Use of an  in vitro 
three- dimensional crypt culture model showed that the TIGAR knockout crypts also 
have a proliferation defect. The defect can be rescued by exogenous antioxidants or 
nucleosides. Interestingly, nucleoside addition was found to help sustain a favorable 
GSH to GSSG ratio [ 72 ]. Overall, these mechanisms can be understood in that 
PFK1 inhibition allows for a buildup of G6P that pushes into the ox-PPP in which a 
rising NADP + to NADPH ratio is furthermore activating G6PD. The NADPH thus 
produced provides reducing power to deal with the oxidative stress. The antioxidant 
effect of TIGAR under hypoxia is partially independent of its BPase activity and 
instead depends on TIGAR translocating to the mitochondria and associating with 
mitochondrial hexokinase-2 [ 73 ]. 
 Glyceraldehyde 3-Phosphate Dehydrogenase Inhibition 
 The redirection of glycolytic ﬂ ux through the ox-PPP to combat oxidative stress is 
also achieved by targeting glycolytic enzymes downstream of PFK1. Frequently, 
the process involves ROS directly oxidizing thiol switches within these enzymes. 
Subsequent to the PFK1 step, aldolase cleaves F-1,6-BP into two three-carbon 
molecules: dihydroxyacetone phosphate (DHAP) and G3P. G3P is the substrate of 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH catalyzes the 
reversible oxidative phosphorylation of G3P to 1,3-bisphosphoglycerate (1,3-BPG) 
using NAD + and inorganic phosphate. 1,3-BPG is a strong product inhibitor of 
GAPDH [ 74 ]. Mechanistically, GAPDH employs a conserved active site cysteine 
(Cys152 in humans) for a nucleophilic attack on the aldehyde moiety of G3P form-
ing a thiohemiacetal that rearranges to an acyl-enzyme intermediate with a hydride 
transfer to NAD + . The acyl-enzyme intermediate is resolved by an inorganic phos-
phate attack [ 74 ]. The same active site cysteine involved in catalysis functions as a 
thiol switch, as discussed below. Interestingly, GAPDH has other enzymatic activities 
including S-nitrolase, ADP-ribosylase, kinase, and peroxidase [ 74 ]. 
 The GAPDH reaction is not at equilibrium and is therefore a potential regulatory 
point of glycolysis [ 75 ]. In mammalian cells, GAPDH is inhibited within minutes 
of exposure to oxidants predominantly via direct enzyme inactivation and loss of the 
NAD + cofactor presumably through PARP activation [ 40 ,  76 ]. The GAPDH active 
site cysteine is highly sensitive to inhibitory oxidative modiﬁ cations of ROS and 
reactive nitrogen oxide species (RNS). With H 2 O 2 , the modiﬁ cations include, in 
order of increasing oxidation, sulfenic, sulﬁ nic, and sulfonic acid. Additionally, the 
active site cysteine can oxidize by forming an intramolecular disulﬁ de with a proximal 
cysteine [ 20 ,  40 ,  77 – 80 ]. 
 Beyond direct ROS thiol oxidation, GAPDH is rapidly S-thiolated following 
both endogenous (e.g., monocyte respiratory bursts) and exogenous oxidative stress. 
S-thiolation is a posttranslational modiﬁ cation in which proteins form mixed disul-
ﬁ des with low molecular weight thiols. In human cells, the majority of adducts are 
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formed using GSH, but free cysteine also contributes. GAPDH S-thiolation is inhibitory. 
Activity can be restored by dithioerythritol (DTE) treatment or if the oxidative 
insult or stimulus is removed, indicating that the inhibition is reversible [ 81 ,  82 ]. 
 S. cerevisiae knockout strains defective in GSH biosynthesis cannot recover 
GAPDH enzymatic activity, suggesting that GSH is necessary to protect against 
irreversible thiol hyperoxidation [ 83 ]. The process seems to be regulated, because 
S-thiolation is speciﬁ c to the Tdh3 isoform of GAPDH in  S. cerevisiae , but not the 
Tdh2 isoform, despite high sequence homology (96 % identity). Tdh3 recovers 
activity within a 2-h period, but not Tdh2. Interestingly, the isozymes are required 
to deal with different types of exogenous oxidative stress—lethal dose versus a 
continuous low-level challenge [ 84 ]. ATP levels plummet following ROS stress as 
both mitochondrial and glycolytic ATP synthesis is inhibited [ 40 ,  76 ]. Protecting 
GAPDH from irreversible oxidation via S-thiolation may allow a cell to quickly 
resume glycolysis and hence ATP production after the stress wanes. Without a 
sufﬁ ciently rapid recovery of ATP synthesis, cell death may ensue. Oxidative stress can 
also induce GAPDH aggregation via intermolecular disulﬁ de bonds dependent on 
the active site cysteine. Such aggregates are found in brain extracts from Alzheimer’s 
disease (AD) patients and may participate in the proapoptotic functions of GAPDH 
[ 20 ,  85 ,  86 ]. Importantly, GAPDH inhibition helps divert glycolytic ﬂ ux into the 
ox-PPP pathway by allowing metabolites to accumulate upstream of the point of 
inhibition consistent with the observed induction of PPP enzymes following H 2 O 2 
treatment (Fig.  3 ) [ 83 ,  87 ]. Triose phosphate isomerase (TPI) immediately precedes 
GAPDH in glycolysis. Both  Caenorhabditis elegans and  S. cerevisiae mutants 
with reduced TPI activity are resistant to oxidative stress. Using a combination of 
genetic knockouts of PPP enzymes and metabolomic studies, it was shown that 
low-TPI- activity mutants or ROS inhibition of GAPDH rerouted ﬂ ux through the 
PPP [ 88 ,  89 ]. Thus, GAPDH is an important target of ROS that mediates cellular 
antioxidant response.
 Pyruvate Kinase M2 Inhibition 
 Pyruvate kinase (PK) catalyzes the ﬁ nal reaction of glycolysis transferring the 
phosphate moiety of phosphoenolpyruvate (PEP) to ADP, thus generating pyruvate 
and ATP. Mammals have four PK isoforms. The liver (PKL) and erythrocyte (PKR) 
isoforms are produced from the  PKLR gene. The PKM1 and PKM2 isoforms derive 
from alternate splicing of exons 9 and 10 of the  PKM gene, respectively [ 90 – 93 ]. 
PKM1 is predominantly expressed in adult differentiated tissues with a high ATP 
demand, such as the brain, heart, and muscle. PKM2 is expressed over the course of 
development, in cancers, and in tissues such as the spleen and lungs [ 94 ,  95 ]. PKM2 
differs from PKM1 in that it has a lower intrinsic enzymatic activity and has unique 
regulatory properties. PKM2 allosteric activators include AMP, the  de novo 
purine synthesis intermediate SAICAR (succinylaminoimidazolecarboxamide 
ribose-5- phosphate), the glycolytic intermediate F-1,6-BP, and the amino acid 
serine [ 95 – 98 ]. Cellular PKM2 is in a dynamic equilibrium between a less active 
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monomeric form and a more active tetrameric form. Mechanistically, F-1,6-BP 
allosterically activates PKM2 by stabilizing the tetramer. Conversely, as F-1,6-BP 
levels drop, the monomeric form prevails, inhibiting PKM2 activity. Thus, F-1,6-BP 
provides a regulatory loop to coordinate PKM2 activity based on the product of the 
critical PFK1 step and glucose availability [ 99 – 101 ]. Phosphotyrosine protein 
binding, tyrosine phosphorylation (Y105), and lysine acetylation (K433) prevent 
F-1,6-BP binding, thereby inhibiting PKM2 activity [ 102 – 104 ]. Surprisingly, mul-
tiple non- glycolytic functions unique to PKM2 have been proposed, including pro-
tein kinase and transcriptional coactivator activities. The role of PKM2 in cancer is 
under intensive study, in part because it has been argued that PKM2 is critical for 
the metabolic rewiring needed to support cancer cell proliferation, and also because 
of its novel non-glycolytic activities [ 96 ,  102 ,  105 – 111 ]. In studying the glycolytic 
function of PKM2 in cancer cells, it has become clear that PKM2 contains a thiol 


































 Fig. 3  Reactive oxygen species (ROS)-mediated inhibition of glycolysis reroutes ﬂ ux into the 
oxidative arm of the pentose phosphate pathway. ROS inactivates glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and the pyruvate kinase isoform PKM2 by directly targeting cysteine 
residues. Alternatively, ROS and UV stress can trigger p53-dependent TIGAR (TP53-induced gly-
colysis and apoptosis regulator) activation that inhibits phosphofructokinase-1 (PFK1). Glycolytic 
inhibition promotes ﬂ ux into the oxidative pentose phosphate pathway to produce NADPH and 
fuel cellular antioxidant systems ( graded green arrow ). For example, NADPH is consumed by 
glutathione reductase (GSR) to recycle oxidized glutathione (GSSG). PKM2 inhibition is unique 
in that it allows for a diversion of ﬂ ux into the serine synthesis pathway. Serine not only contributes 
to the synthesis of macromolecules but is also a precursor for glutathione (GSH). Serine synthesis 
is activated by a buildup of 2-phosphoglycerate (2PG), which prevents 3-phosphoglycerate (3PG)-
induced inhibition of the oxidative pentose phosphate arm. Enzymes are shown in  purple . ROS 
targets are shown in  red 
 
Diverting Glycolysis to Combat Oxidative Stress
14
 Across diverse organisms ranging from  Escherichia coli to humans, PK activity 
is inhibited by oxidative stresses [ 86 ,  112 – 114 ]. One of the earlier observations was 
that  E. coli PK stored cold for prolonged periods of time without a reducing agent 
lost activity. Activity was unresponsive to the conventional activators AMP and 
F-1,6-BP, but could be recovered by incubating the inactive species with the 
reducing agents beta-mercaptoethanol or dithiothreitol (DTT) [ 113 ]. Whether the 
inhibition was an in vitro artifact or physiologically relevant was unclear. Prompted 
by the link between oxidative stress and Alzheimers disease (AD), proteomic studies 
to identify oxidatively modiﬁ ed proteins in the hippocampi of patients suffering 
from mild cognitive impairment, a condition that commonly progresses to AD, 
revealed that PKM2 was signiﬁ cantly more carboxylated in those patients than in 
controls [ 86 ]. Interestingly, in  S. cerevisiae , low PK activity activates respiration. 
Despite increased oxidative phosphorylation, increased ROS production is suppressed, 
hinting at some antioxidant function of low PK activity [ 115 ]. PEP functions as a 
competitive inhibitor of human and yeast TPI. Crystallographic studies indicate 
that the PKM2 substrate PEP binds directly in the TPI catalytic pocket [ 115 ,  116 ]. 
Thus, low PK activity enables PEP to accumulate, to form a negative feedback loop 
that reduces GAPDH substrate availability by preventing the interconversion of 
DHAP and G3P. TPI inhibition redirects ﬂ ux into the PPP pathway and protects 
yeast from a variety of oxidative stresses explaining how the increased respiration 
resulting from low PK activity does not promote ROS [ 115 ]. Previous work had 
shown that TPI loss-of-function mutants in  S. cerevisiae and  C. elegans are similarly 
resistant to exogenous oxidative stresses in a manner genetically dependent on PPP 
enzymes [ 88 ,  89 ]. 
 Studying PKM2 in the context of cancer cell metabolism not only elucidated the 
mechanism whereby ROS inactivates PKM2, but also identiﬁ ed the functional sig-
niﬁ cance of PMK2 inhibition [ 112 ]. In human cancer cells, several types of oxida-
tive stresses, including H 2 O 2 , diamide, and hypoxia, inactivate PKM2. DTT restores 
PKM2 activity to levels commensurate with those of untreated cells. Neither PKM1 
nor heteromers of PKM1 and PKM2 are inhibited by oxidation. Oxidation was 
shown to directly target Cys358 of PMK2 and decrease the levels of the active 
tetramer thereby explaining the reduced PKM2 activity. Mutating Cys358 to serine 
abrogates oxidative stress–induced PKM2 dissociation thus preserving the enzy-
matic activity under stress. Adding small molecule activators that bind to the PKM2 
subunit interface and stabilize the tetrameric form similarly prevent ROS-induced 
dissociation and loss of PKM2 activity [ 101 ,  112 ]. Functionally, PKM2 inhibition 
allows cells to increase G6P levels and ox-PPP pathway ﬂ ux to generate more 
NADPH and hence preserve reduced GSH and prevent intracellular ROS accumula-
tion (Fig.  3 ). The ROS inducible PKM2 inhibition not only translates into greater 
survival when cells are exposed to acute oxidative stress, or chronic ROS stress 
induced by hypoxia, but also increases the tumorigenic potential of cells in xenografts. 
Both activator-treated and PKM2 C358S mutant cells are defective in their antioxidant 
response indicating how critical tetramer dissociation is to protect against oxidative 
stress [ 112 ]. ROS-mediated PKM2 inhibition also suggests a mechanism whereby 
PEP levels can accumulate and inhibit TPI, as in the yeast study described above. 
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PEP inhibition of recombinant human TPI in biochemical assays has been 
demonstrated [ 115 ,  116 ]. Whether TPI inhibition is necessary for the protective 
effects of PKM2 inhibition in human cells remains unknown. PKM2 has been 
reported to interact with the HIF1α and HIF2α transcription factors to promote 
expression of glycolytic genes (e.g.,  SLC2A1, LDHA, PDK1 ) and  VEGFA . Thus, 
PKM2 may also promote ROS detoxiﬁ cation by alleviating tumor hypoxia [ 117 ,  118 ]. 
 De Novo Serine Synthesis 
 While PKM2 inhibition allows cells to fend off ROS by activating the ox-PPP, it 
may also help cells deal with more chronic oxidative stress by enabling a buildup of 
the glycolytic intermediate 3-phosphoglycerate (3PG). 3PG can be diverted into the 
phosphoserine pathway for  de novo serine synthesis [ 119 – 121 ]. Alternatively, serine 
can be imported from the extracellular space by a variety of transporters, including 
the commonly expressed ASC system (ASCT1 and ASCT2), that mediate the 
symport of serine, alanine, or cysteine with sodium [ 122 ,  123 ]. Serine plays a vital 
role in the antioxidant defense system because it is a precursor for the synthesis of 
GSH (Fig.  3 ). The phosphoserine synthesis pathway consists of three sequential 
reactions: ﬁ rst, 3-phosphoglycerate dehydrogenase (PHGDH) oxidizes 3PG using 
NAD + to give 3-phosphohydroxypyruvate (3-PHP); second, the PLP-dependent 
phosphoserine aminotransferase (PSAT1) transaminates 3- phosphohydroxypyruvate 
to phosphoserine (PSER) utilizing glutamate as the nitrogen donor; ﬁ nally, phos-
phoserine phosphatase (PSPH) hydrolyzes the PSER phosphate group to release 
serine [ 119 – 121 ]. PHGDH, which catalyzes the ﬁ rst committed step of the pathway, 
was found to be focally ampliﬁ ed in human tumors, particularly those of the breast 
and melanoma. Cancer cell lines harboring the ampliﬁ cation, and some non- 
ampliﬁ ed lines overexpressing PHGDH, are uniquely sensitive to knockdown of any 
enzyme in the pathway [ 124 ,  125 ]. Although some have speculated, the mechanism 
by which the phosphoserine pathway promotes tumorigenesis and why extracellular 
serine is unable to compensate remain to be determined [ 121 ]. Interestingly, 3PG is 
a competitive inhibitor of PGD. Thus, an extensive buildup of 3PG can inhibit 
ox-PPP NADPH production. 3PG levels are kept sufﬁ ciently low via a feedback 
loop that activates 3PG diversion into the phosphoserine pathway. In glycolysis, 3PG 
is converted to 2-phosphoglycerate (2PG) by phosphoglycerate mutase 1 (PGAM1). 
2PG activates PHGDH to deplete excess 3PG, thereby promoting the synthesis of 
serine and preventing ox-PPP inhibition [ 126 ]. 
 Oxidative stress is known to damage all three principal classes of macromole-
cules -lipids, nucleic acids, and protein [ 11 ]. Macromolecules that cannot be 
repaired by the cellular antioxidant systems can be replaced by newly synthesized 
molecules. Serine is an important precursor for  de novo macromolecule synthesis. 
Serine is directly incorporated into proteins and the head groups of certain abundant 
lipids such as sphingosine and phosphatidylserine [ 127 ,  128 ]. Serine hydroxymeth-
yltransferases (SHMTs) convert serine to glycine in a retro-aldol cleavage reaction 
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concomitantly charging the folate pool with a methylene group. In fact, the SHMT 
reaction is a major source of one-carbon units for the folate cycle. Glycine and the 
folate cycle donate carbon for the synthesis of purine and pyrimidines [ 129 ]. Thus, 
by contributing to protein, nucleic acid, and lipid synthesis, serine can help cells 
recover from oxidative damage to macromolecules. 
 The importance of serine in dealing with oxidative stress is further highlighted 
by its contribution to GSH synthesis. GSH is an enzymatically synthesized tripep-
tide composed of glutamate, cysteine and glycine. Cysteine and glycine can both be 
produced from serine or imported from the extracellular space. Serine combines 
with homocysteine in the transsulfuration pathway to yield cystathionine, which is 
subsequently hydrolyzed to cysteine and homoserine [ 42 ]. Glycine is formed from 
serine via SHMTs as described above. Thus, up to two moles of serine can be con-
sumed per mole of GSH produced. In certain cell types, a large fraction of cytosolic 
NADPH, comparable to that produced via the PPP, is produced from the oxidation 
of folate cycle one-carbon units derived from serine via the SHMT reaction [ 58 ]. 
Hence, the conversion of serine to glycine may have the twin beneﬁ ts of fuelling 
GSH synthesis and providing the NADPH-reducing power to maintain GSH in its 
reduced form via glutathione reductase. Alternatively, the NADPH could fuel fatty 
acid synthesis to aid recovery from lipid oxidation damage [ 130 ]. There is signiﬁ -
cant heterogeneity in the propensity of different cell types to synthesize serine  de 
novo suggesting that the anabolic functions of serine following oxidative stress may 
similarly diverge across cell types [ 124 ,  125 ]. 
 Conclusion 
 We have seen that ROS can inhibit glycolysis at multiple nodes. A recurring theme 
is that the inhibition of glycolysis allows cells to divert ﬂ ux into the ox-PPP path-
way to promote NADPH synthesis and protect against oxidative stress. However, 
there are also differences depending on the exact point of inhibition. Inhibition at 
the PKM2 step allows cells to promote ﬂ ux into the serine synthesis pathway, while 
PFK1 and GAPDH inhibition does not. Furthermore, both GAPDH and PKM2 
inhibition can promote dihydroxyacetone phosphate accumulation, which is an 
important precursor for the glycerol-3-phosphate shuttle and the synthesis of glycerol 
needed for triglycerides [ 88 ,  115 ]. As of yet, we only have a limited understanding 
of what determines which glycolytic node is targeted by ROS and what the advan-
tages are for each. For example, both GAPDH and PKM2 are inhibited by hydrogen 
peroxide, but is the order of inactivation simply determined by the relative order of 
the redox potentials of their respective cysteines or are other mechanisms involved 
[ 81 ,  112 ]? Presumably, GAPDH inhibition overrides PKM2 inhibition, as it is 
upstream of the latter. One could imagine a hierarchical model where PKM2 
responds ﬁ rst to oxidative stress, then GAPDH, and ﬁ nally PFK1. Given the impor-
tance of ROS in tumor development and anticancer therapies, a better understanding 
of how central metabolism and ROS intertwine could uncover interesting biology 
and suggest mechanisms to enhance current therapies [ 1 ]. 
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